Cargando…
Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases
Mediator-associated kinases CDK8/19 are context-dependent drivers or suppressors of tumorigenesis. Their inhibition is predicted to have pleiotropic effects, but it is unclear whether this will impact on the clinical utility of CDK8/19 inhibitors. We discovered two series of potent chemical probes w...
Autores principales: | Clarke, Paul A, Ortiz-Ruiz, Maria-Jesus, TePoele, Robert, Adeniji-Popoola, Olajumoke, Box, Gary, Court, Will, Czasch, Stephanie, El Bawab, Samer, Esdar, Christina, Ewan, Ken, Gowan, Sharon, De Haven Brandon, Alexis, Hewitt, Phillip, Hobbs, Stephen M, Kaufmann, Wolfgang, Mallinger, Aurélie, Raynaud, Florence, Roe, Toby, Rohdich, Felix, Schiemann, Kai, Simon, Stephanie, Schneider, Richard, Valenti, Melanie, Weigt, Stefan, Blagg, Julian, Blaukat, Andree, Dale, Trevor C, Eccles, Suzanne A, Hecht, Stefan, Urbahns, Klaus, Workman, Paul, Wienke, Dirk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224920/ https://www.ncbi.nlm.nih.gov/pubmed/27935476 http://dx.doi.org/10.7554/eLife.20722 |
Ejemplares similares
-
A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease
por: Dale, Trevor, et al.
Publicado: (2015) -
Discovery of Potent, Orally
Bioavailable, Small-Molecule
Inhibitors of WNT Signaling from a Cell-Based Pathway Screen
por: Mallinger, Aurélie, et al.
Publicado: (2015) -
2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with
Potent, Selective Affinity for CDK8/19
por: Mallinger, Aurélie, et al.
Publicado: (2016) -
Discovery of Potent,
Selective, and Orally Bioavailable
Small-Molecule Modulators of the Mediator Complex-Associated Kinases
CDK8 and CDK19
por: Mallinger, Aurélie, et al.
Publicado: (2016) -
Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a
Dual FLT3/Aurora
Kinase Inhibitor as an Orally Bioavailable Preclinical Development
Candidate for the Treatment of Acute Myeloid Leukemia
por: Bavetsias, Vassilios, et al.
Publicado: (2012)